Amneal Pharma ( (AMRX) ) has released its Q2 earnings. Here is a breakdown of the information Amneal Pharma presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a global biopharmaceutical company that develops, manufactures, and distributes a diverse portfolio of over 280 pharmaceutical products, focusing on affordable medicines and specialty pharmaceuticals primarily in the United States.
Amneal Pharmaceuticals reported its financial results for the second quarter of 2025, showcasing a net revenue of $725 million and a GAAP net income of $22 million. The company also highlighted the strong commercial uptake of its Parkinson’s disease treatment, CREXONT®, and the FDA approval of Brekiya® autoinjector for migraines and cluster headaches.
Key financial metrics from the quarter include a 3% increase in net revenue compared to the same period in 2024, driven by a 23% rise in specialty net revenue. The company’s adjusted EBITDA reached $184 million, marking a 13% increase, while adjusted diluted earnings per share rose by 56% to $0.25. Amneal also successfully completed a debt refinancing, reducing interest costs and extending maturities to 2032.
Looking ahead, Amneal has raised its full-year 2025 financial guidance, reflecting confidence in its growth strategy and financial performance. The company anticipates net revenue between $3.0 billion and $3.1 billion, with adjusted EBITDA expected to range from $665 million to $685 million.
Amneal’s management remains optimistic about the company’s long-term growth prospects, supported by its diversified pharmaceutical business and strengthened capital structure, positioning it well for future success.